Delivering more for human health and beyond
Medlab Clinical (ASX: MDC) is an Australian publicly listed biotechnology company with a global market opportunity. Our team of scientists, researchers and doctors are dedicated to building products that are scientifically optimised for a better life, specialising in oncology and enhanced drug delivery.
Medlab has a portfolio of novel cannabinoid-based assets enhanced by our leading drug delivery platform. Our lead drug candidate, NanaBis™, is an opioid alternative for cancer-induced pain management, with company-making potential and a global market opportunity.
Core to our value proposition is NanoCelle®, our patented sub-micron drug delivery platform that vastly improves drug solubility issues and enables faster absorption and metabolism of active ingredients. NanoCelle® underpins our growth strategy by offering near-term partnering opportunities whilst enhancing our pharma portfolio.
Investment Highlights
- Patented NanoCelle® drug delivery platform with value creation optionality, enhancing our product portfolio whilst offering near term partnering opportunities
- World-class Board, management and scientific consulting team with strong experience bringing novel therapeutics to market
- Scientifically optimised portfolio of cannabinoid therapeutics addressing a global unmet need in oncology areas including pain management
- Lead candidate NanaBis™ Phase I/II primary and secondary endpoints met in bone cancer patients, replicated in a real-world observational study. Stage III commencing in near-term with robust and clear drug pathway in US, EU and Australia
- NanaBis™ proof of concept established and early revenue being generated via Special Access Scheme
Have an investor relationship question, you can book a meeting with our CEO, Dr Sean Hall
Sign up for Investor Updates
Stay up-to-date with the latest investor news, presentations and videos from Medlab sent directly to your email address.
Latest Investor News
Medlab to be granted European patent for NanoCelle® drug delivery platform
European Patent Office issues Notice of Intention to grant Medlab Clinical patent for NanoCelle® drug delivery platform
2021-04-07
Novartis’ Managing Director of Oncology (ANZ/NZ) joins Medlab Clinical board
Medlab Clinical appoints Novartis' Managing Director of Oncology for Australia and New Zealand as Non-Executive Director.
2021-03-23
Medlab Clinical raises $15 million and Leading Executive Joins Board
Medlab Clinical successfully raised $15 million to help fund its upcoming Phase III clinical trial and has extended its board expertise with the appointment of leading pharmaceutical executive Mrs Cheryl Maley.
2021-03-19
Medlab Clinical looks for $15 million equity injection
Medlab clinical looks to raise $15 million to fund its Phase III trial. Read more here.
2021-03-17
Medlab Clinical partners with Arrotex
Medlab Clinical partners with Arrotex to accelerate NanoCBD availability in Australian pharmacies
2021-02-18
Medlab to confirm NanaBis’ potential as non-opioid analgesic in phase III trial
Read the write up from Small Caps about Medlab's non-opioid pain treatment
2021-01-27
Ausbiz interview of CEO Sean Hall
Ausbiz interviews the CEO of Medlab, Sean Hall about the future of Medlab
2021-01-27
IND Acceptance Investor Update
NanaBis has been granted IND status by the US FDA, allowing Medlab to initiate its pivotal Phase III study at US sites
2021-01-19
Switzer Investor Day
4th Small and Micro-Cap Virtual Investor Day
2020-12-02
Ausbiz interview
Ausbiz interviews the CEO of Medlab, Sean Hall about the future of Medlab
2020-12-02
Nanabis Presentation
Learn more about NanaBis and the significant opportunity ahead
2020-09-01
StockPal Webinar
In this part two of a four-part webinar recap, Sean Hall, Chief Executive Officer and Managing Director of Medlab (ASX:MDC) presented on the company’s latest announcements and updates while answering some questions during the Q&A session at the end.
2020-08-11
Page No.
